摘要
目的对比两种化疗方案治疗耐多药肺结核(MDR-PTB)的疗效。方法将146例MDR-PTB患者随机分成治疗组与对照组,治疗组84例患者以左氧氟沙星及阿米卡星为主,联合应用利福喷汀、对氨基水杨酸异烟肼、吡嗪酰胺、乙胺丁醇治疗;对照组62例患者用氧氟沙星、阿米卡星,联用异烟肼、利福平、吡嗪酰胺、乙胺丁醇治疗,疗程均为18个月。结果疗程结束治疗组痰菌阴转率为85·7%,病灶显效率为50·0%,空洞闭合率为62·3%,与对照组的59·0%、26·9%、39·7%比较差别均有显著性意义(P<0·01);治疗组药物不良反应率为22·6%,对照组为26·9%,两者间差别无显著性意义(P>0·05);治疗组患者2年细菌学复发率为2·8%,对照组为22·5%,两者间差别有显著性意义(P<0·01)。结论以左氧氟沙星、阿米卡星为主的方案治疗MDR-PTB,可显著提高痰菌阴转率,降低复发率,且安全可靠,值得推广。
Objective To contrast the efficacy of the two combination chemotherapy plans with LVFX, AMK in the treatment of mul -- drug resistant pulmonary tuberculosis [ MDR - PTB ], Methods 162 cases of these patients were divided into study group and control group according to different degree of drug resistance. 84 cases were in the study group, its plan included mainly LVFX and AMK in combination with RFE, PAS, PZA and EMB, 78 cases was in the control group, its plan mainly included OVFX, AMK in combination with INH, RFP, PZA and EMB, Results At the end of the treatment courses, the sputum negative conversion rate of the study group was respectively 85.7% ; the radiographic improvement rate was 50. 0%, The clusure rate was 62. 3%, Accordingly, the sputum negative conversion rate of control group was respectively 59. 0%, the radiographic improvement rate was 26. 9%, the clusure rate was 39.7%. There was marked difference between the study group and the control group （ P 〈0. 01 ）, The occurrence rate of drug side - effects in the study group was 22.6% ; in the control group it was 26.9%, The difference between the study group and control group was not significant （ P 〉 0. 05）. The recurrence rates of study group was 2.8% ; the control group was 22. 5%. The difference between study group and control group was prominent （ P 〈0.01）. Conclusion The study group treatment plans could enhance sputum negative conversion rates and lower their recurrence rates, which were safe, dependable, and worth popularizing.
出处
《中国全科医学》
CAS
CSCD
2005年第18期1498-1499,共2页
Chinese General Practice
关键词
结核
肺
药物疗法
耐多药肺结核
Tuberculosis, pulmonary
Drug therphy
MDR - PTB
